In our 2-year longitudinal study, the high baseline MCP-1 level is associated with the rate of cognitive decline in AD and MCI patients and may indicate the deleterious effects of MCP-1 during AD and MCI as well as suggest that plasma MCP-1 levels may be useful for monitoring disease progression. The gene discussed is CCL2; the disease is Mental deterioration.